2Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest, 2009, 136(1): 260-271.
3Goldstraw P, CrowleyJ, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.J Thorac Oncol, 2007, 2(8): 706-714.
4Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol, 2004, 22: 329-360.
5Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
6Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N EnglJ Med, 2012, 366(26): 2443-2454.
7Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N EnglJ Med, 2012, 366(26): 2455-2465.
8Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther, 2013, 13(6): 847-861.
9Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 2013, 13(4): 227-242.
10Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, 26: 677-704.
